Y Intercept Hong Kong Ltd Buys New Shares in CryoPort, Inc. $CYRX

Y Intercept Hong Kong Ltd acquired a new position in shares of CryoPort, Inc. (NASDAQ:CYRX) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 39,114 shares of the company’s stock, valued at approximately $292,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of CryoPort as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. increased its holdings in shares of CryoPort by 154.5% in the first quarter. Russell Investments Group Ltd. now owns 32,761 shares of the company’s stock worth $199,000 after purchasing an additional 19,886 shares during the period. Assenagon Asset Management S.A. increased its holdings in CryoPort by 7.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company’s stock worth $8,135,000 after buying an additional 73,949 shares in the last quarter. Conestoga Capital Advisors LLC grew its position in shares of CryoPort by 55.9% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 110,557 shares of the company’s stock valued at $825,000 after acquiring an additional 39,640 shares during the period. CWM LLC raised its stake in CryoPort by 1,437.0% during the 1st quarter. CWM LLC now owns 11,328 shares of the company’s stock valued at $69,000 after purchasing an additional 10,591 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its position in CryoPort by 54.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 113,235 shares of the company’s stock worth $688,000 after purchasing an additional 39,698 shares during the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the sale, the chief financial officer directly owned 207,213 shares in the company, valued at $1,796,536.71. The trade was a 4.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert J. Hariri sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $9.71, for a total transaction of $242,750.00. Following the completion of the sale, the director directly owned 51,275 shares of the company’s stock, valued at $497,880.25. The trade was a 32.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 39,300 shares of company stock valued at $366,381 over the last three months. Corporate insiders own 10.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on CYRX shares. KeyCorp raised CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price on the stock in a research report on Wednesday, August 6th. Leerink Partners upgraded shares of CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a report on Wednesday, August 6th. Needham & Company LLC lifted their price target on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday. UBS Group increased their price target on CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday. Finally, Stephens initiated coverage on CryoPort in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.83.

CryoPort Trading Up 0.6%

Shares of NASDAQ CYRX opened at $8.38 on Friday. CryoPort, Inc. has a 12-month low of $4.58 and a 12-month high of $11.44. The company has a market cap of $419.56 million, a price-to-earnings ratio of 6.30 and a beta of 1.58. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39. The stock’s 50 day simple moving average is $9.53 and its 200 day simple moving average is $7.97.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $44.23 million during the quarter, compared to the consensus estimate of $41.22 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. Equities research analysts expect that CryoPort, Inc. will post -0.99 EPS for the current year.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.